Uno studio per valutare l'efficacia e la sicurezza di JNJ-77242113 rispetto al placebo e ustekinumab nei partecipanti con psoriasi di placca moderata a grave (ICONIC-ASCEND)
Uno studio multicentrico di fase 3, randomizzato, in doppio cieco, controllato con placebo e Ustekinumab attivo controllato dal comparatore attivo per valutare l'efficacia e la sicurezza di JNJ-77242113 per il trattamento dei partecipanti con psoriasi della placca moderata a grave
The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
-
Barrio Gral Paz Cba Capital, Argentina, X5000
- Consultora Integral de Salud SRL
-
Buenos Aires, Argentina, B1643CRO
- Instituto Medico De Alta Complejidad (IMAC)
-
Buenos Aires, Argentina, C1417EYG
- Mindout Research
-
Buenos Aires, Argentina, C1425
- Instituto de Neumonologia y Dermatologia
-
CABA, Argentina, C1061AAS
- CIPREC
-
CABA, Argentina, C1199ABB
- Hospital Italiano de Buenos Aires
-
CABA, Argentina, C1055AAO
- Buenos Aires Skin
-
CABA, Argentina, C1056ABH
- Investigaciones Medicas IMOBA SRL
-
CABA, Argentina, C1128
- Mautalen Salud e Investigacion
-
Caba, Argentina, C1122AAF
- Halitus Instituto Medico S.A. - Dermatologia y Estetica
-
Rosario, Argentina, S2000DBS
- Instituto De Especialidades De La Salud SRL
-
San Fernando, Argentina, B1646
- MR Medicina Reumatologica
-
San Miguel de Tucumán, Argentina, T4000
- Instituto de Investigaciones Medicas Tucuman
-
-
-
-
-
Clayton, Australia, 3168
- Monash Medical Centre
-
Coorparoo, Australia, 4151
- Cornerstone Dermatology
-
Greenslopes, Australia, 4120
- Veracity Clinical Research
-
Kogarah, Australia, 2217
- Premier Specialists
-
Melbourne, Australia, 3004
- The Alfred Hospital
-
Melbourne, Australia, 3050
- Royal Melbourne Hospital
-
Mitcham, Australia, 3132
- ISHI dermatology
-
Westmead, Australia, 2145
- Westmead Hospital
-
-
-
-
-
Feldkirch, Austria, 6800
- LKH Feldkirch
-
Linz, Austria, 4020
- Kepler Universitatsklinikum GmbH
-
Sankt Pölten, Austria, 3100
- Universtitatsklinikum St Poelten
-
Vienna, Austria, 1090
- Allgemeines Krankenhaus der Stadt Wien
-
-
-
-
-
Brussels, Belgio, 1090
- UZ Brussel
-
Ghent, Belgio, 9000
- Ghent University Hospital
-
Ghent, Belgio, 9000
- AZ St. Lucas
-
Leuven, Belgio, 3000
- Universitair Ziekenhuis Leuven
-
Liège, Belgio, 4000
- Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman
-
Maldegem, Belgio, 9990
- Dermatologie Maldegem
-
-
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1E 1V4
- Skincare Studio Inc Dermatology Clinical Trials
-
-
Ontario
-
Ajax, Ontario, Canada, L1S7K8
- CCA Medical Research Corporation
-
Barrie, Ontario, Canada, L4M 7G1
- SimcoDerm Medical and Surgical Dermatology Centre
-
Hamilton, Ontario, Canada, L8N 1Y2
- Dermatrials Research
-
London, Ontario, Canada, N6A 5R9
- Lovegrove Dermatology
-
Markham, Ontario, Canada, L3P 1X3
- Lynderm Research Inc.
-
Waterloo, Ontario, Canada, N2J 1C4
- Alliance Clinical Trials
-
-
Quebec
-
Montreal, Quebec, Canada, H2X 2V1
- Innovaderm Research Inc.
-
Québec, Quebec, Canada, G1W 4R4
- The Centre de recherche Saint-Louis
-
-
-
-
-
Aalborg, Danimarca, 9100
- Aalborg Sygehus Syd
-
Aarhus, Danimarca, 8200
- Aarhus University Hospital
-
Hellerup, Danimarca, 2900
- Gentofte Hospital
-
København NV, Danimarca, 2400
- Bispebjerg Hospital
-
Odense, Danimarca, 5000
- Odense University Hospital
-
Roskilde, Danimarca, 4000
- Sjællands University hospital
-
-
-
-
-
Augsburg, Germania, 86179
- Klinikum Augsburg
-
Bad Bentheim, Germania, 48455
- Fachklinik Bad Bentheim
-
Berlin, Germania, 10789
- ISA - Interdisciplinary Study Association GmbH
-
Bonn, Germania, 53127
- Universitatsklinikum Bonn
-
Bramsche, Germania, 49565
- Studienzentrum an der Hase GbR
-
Darmstadt, Germania, 64283
- Rosenpark Research GmbH
-
Dresden, Germania, 01307
- Medizinische Fakultaet Carl Gustav Carus Technische Universitaet Dresden
-
Friedrichshafen, Germania, 88045
- Derma-Study-Center Friedrichshafen GmbH
-
Kiel, Germania, 24105
- Universitaetsklinikum Schleswig Holstein Campus Kiel
-
Langenau, Germania, 89129
- Studienzentrum Dr Schwarz Germany
-
Mahlow, Germania, 15831
- Dermatologie Mahlow
-
Mainz, Germania, 55128
- Gemeinschaftspraxis Dres. Quist
-
Münster, Germania, 48149
- Universitaetsklinikum Muenster
-
Witten, Germania, 58453
- Hautarztpraxis
-
-
-
-
-
Bialystok, Polonia, 15 375
- Specderm Poznanska sp j
-
Bialystok, Polonia, 15-351
- Osteo-Medic s.c A. Racewicz, J Supronik
-
Elblag, Polonia, 82 300
- Centrum Kliniczno Badawcze J Brzezicki B Gornikiewicz Brzezicka Lekarze Spolka Partnerska
-
Katowice, Polonia, 40 568
- Care Clinic Sp z o o
-
Krakow, Polonia, 30 002
- Specjalistyczny gabinet dermatologiczny Aplikacyjno Badawczy Marek Brzewski Pawel Brzewski Spolka Cywilna
-
Lodz, Polonia, 90-265
- Dermed Centrum Medyczne Sp z o o
-
Olsztyn, Polonia, 10-117
- Etyka Osrodek Badan Klinicznych
-
Poznan, Polonia, 60 529
- SOLUMED Centrum Medyczne
-
Skierniewice, Polonia, 96 100
- Velocity Nova Sp z o o
-
Warsaw, Polonia, 02 661
- Magdalena Opadczuk Carpe Diem Centrum Medycyny Estetycznej
-
Warsaw, Polonia, 02 953
- Klinika Ambroziak Dermatologia
-
Wroclaw, Polonia, 52 416
- Centrum Medyczne Oporow
-
Wroclaw, Polonia, 51 685
- WroMedica I Bielicka A Strzalkowska s c
-
-
-
-
-
Guimarães, Portogallo, 4835 044
- Uls Alto Ave - Hosp. Sra. Da Oliveira Guimaraes
-
Leiria, Portogallo, 2410 197
- Unidade Local De Saude Da Regiao De Leiria Epe
-
Lisbon, Portogallo, 1169 050
- Uls Sao Jose - Hosp. Sto Antonio Dos Capuchos
-
Lisbon, Portogallo, 1998 018
- Hosp. Cuf Descobertas
-
Porto, Portogallo, 4099 001
- Ulssa Hosp. Santo Antonio
-
-
-
-
-
Dudley, Regno Unito, DY1 2HQ
- Dudley Group NHS Foundation Trust
-
Harrow, Regno Unito, HA1 3UJ
- London North West University Healthcare NHS Trust
-
Kings Lynn, Regno Unito, PE30 4ET
- The Queen Elizabeth Hospital NHS Foundation Trust
-
London, Regno Unito, SE1 9RT
- Guys and St Thomas NHS Foundation Trust
-
Reading, Regno Unito, RG1 5AN
- Royal Berkshire Hospital
-
Salford, Regno Unito, M6 8HD
- Salford Royal Hospital
-
Southampton, Regno Unito, So166yd
- University Hospital Southampton
-
Wakefield, Regno Unito, WF1 4DG
- Mid Yorkshire Hospital NHS Trust- Pinderfields Hospital
-
-
-
-
-
Alicante, Spagna, 03010
- Hosp. Gral. Univ. Dr. Balmis
-
Barakaldo, Spagna, 48902
- Hosp. Univ. de Cruces
-
Barcelona, Spagna, 08036
- Hosp. Clinic de Barcelona
-
Granada, Spagna, 18016
- Hosp. Univ. San Cecilio
-
Madrid, Spagna, 28041
- Hosp. Univ. 12 de Octubre
-
Madrid, Spagna, 28006
- Hosp. Univ. de La Princesa
-
Madrid, Spagna, 28002
- Grupo Dermatologico Y Estetico Pedro Jaen
-
Manises, Spagna, 46940
- Hosp. de Manises
-
Santiago Compostela, Spagna, 15706
- Hosp. Clinico Univ. de Santiago
-
Seville, Spagna, 41009
- Hosp. Virgen Macarena
-
Seville, Spagna, 41014
- Hosp. Ntra. Sra. de Valme
-
Valencia, Spagna, 46026
- Hosp. Univ. I Politecni La Fe
-
Villajoyosa, Spagna, 03570
- Hosp. de La Marina Baixa
-
Zaragoza, Spagna, 50009
- Hosp. Clinico Univ. Lozano Blesa
-
Zaragoza, Spagna, 50009
- Hosp. Univ. Miguel Servet
-
-
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35244
- Cahaba Research Inc
-
-
California
-
Encinitas, California, Stati Uniti, 92024
- California Dermatology & Clinical Research Institute
-
Encino, California, Stati Uniti, 91436
- T Joseph Raoof Md Inc
-
Fountain Valley, California, Stati Uniti, 92708
- First OC Dermatology
-
Oceanside, California, Stati Uniti, 92056
- Dermatologist Medical Group of North County, Inc.
-
Rocklin, California, Stati Uniti, 95765
- NorCal Clinical Research
-
Sacramento, California, Stati Uniti, 95815
- Integrative Skin Science and Research
-
San Diego, California, Stati Uniti, 92103
- MedDerm Associates
-
Santa Ana, California, Stati Uniti, 92701
- Southern California Dermatology
-
Sylmar, California, Stati Uniti, 91342
- Olive View-UCLA Education & Research Institute
-
-
Connecticut
-
Farmington, Connecticut, Stati Uniti, 06030
- University of Conn Health Center
-
-
Florida
-
Miami, Florida, Stati Uniti, 33155
- Bioclinical Research Alliance Inc.
-
Miami, Florida, Stati Uniti, 33126
- Driven Research LLC
-
Ocala, Florida, Stati Uniti, 34470
- Renstar Medical Research
-
Tampa, Florida, Stati Uniti, 33613
- Forcare Clinical Research Inc
-
-
Georgia
-
Alpharetta, Georgia, Stati Uniti, 30022
- Hamilton Research LLC
-
-
Illinois
-
Skokie, Illinois, Stati Uniti, 60076
- Northshore Medical Group
-
-
Indiana
-
Plainfield, Indiana, Stati Uniti, 46168
- Indiana Clinical Trial Center
-
-
Iowa
-
Iowa City, Iowa, Stati Uniti, 52242
- University of Iowa
-
-
Kentucky
-
Bowling Green, Kentucky, Stati Uniti, 42104
- Equity Medical
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02111
- Tufts Medical Center
-
Brighton, Massachusetts, Stati Uniti, 02135
- Metro Boston Clinical Partners
-
-
Michigan
-
Caledonia, Michigan, Stati Uniti, 49316
- The Derm Institute of West Michigan
-
Detroit, Michigan, Stati Uniti, 48202
- Henry Ford Hospital
-
Fort Gratiot, Michigan, Stati Uniti, 48059
- Hamzavi Dermatology
-
Troy, Michigan, Stati Uniti, 48084
- Somerset Skin Centre
-
-
Minnesota
-
New Brighton, Minnesota, Stati Uniti, 55112
- Minnesota Clinical Study Center
-
-
Missouri
-
Kirksville, Missouri, Stati Uniti, 63501
- Cleaver Dermatology
-
Saint Joseph, Missouri, Stati Uniti, 64506
- MediSearch Clinical Trials
-
-
New York
-
New York, New York, Stati Uniti, 10075
- Sadick Research Group
-
New York, New York, Stati Uniti, 10028
- Mount Sinai Doctors Dermatology
-
-
North Carolina
-
Wilmington, North Carolina, Stati Uniti, 28405
- Wilmington Dermatology Center
-
-
Ohio
-
Boardman, Ohio, Stati Uniti, 44512
- Optima Research
-
Mayfield Heights, Ohio, Stati Uniti, 44124
- Apex Dermatology Mayfield Heights
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97210
- Oregon Dermatology and Research Center
-
Portland, Oregon, Stati Uniti, 97201
- Oregon Medical Research Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19114
- Clinical Research Philadelphia
-
Pittsburgh, Pennsylvania, Stati Uniti, 15213
- UPMC Department of Dermatology
-
-
South Dakota
-
Rapid City, South Dakota, Stati Uniti, 57702
- Health Concepts
-
-
Tennessee
-
Nashville, Tennessee, Stati Uniti, 37211
- Advanced Research Experts PLLC
-
-
Texas
-
Arlington, Texas, Stati Uniti, 76011
- Arlington Research Center, Inc.
-
Dallas, Texas, Stati Uniti, 75231
- Modern Research Associates PLLC
-
Houston, Texas, Stati Uniti, 77004
- Center for Clinical Studies 1
-
San Antonio, Texas, Stati Uniti, 78218
- Texas Dermatology and Laser Specialists
-
San Antonio, Texas, Stati Uniti, 78213
- Progressive Clinical Research
-
Webster, Texas, Stati Uniti, 77598
- Center for Clinical Studies
-
-
Utah
-
West Valley City, Utah, Stati Uniti, 84120
- Kalo Clinical Research
-
-
Washington
-
Mill Creek, Washington, Stati Uniti, 98012
- Frontier Derm Partners CRO, LLC
-
-
-
-
-
Budapest, Ungheria, 1036
- Obudai Egeszsegugyi Centrum Kft
-
Budapest, Ungheria, 1152
- Uno Medical Trials Ltd.
-
Debrecen, Ungheria, 4032
- Debreceni Egyetem Klinikai Kozpont
-
Debrecen, Ungheria, 4031
- Derma-B Kft
-
Gyula, Ungheria, 5700
- Synexus Magyarorszag Kft
-
Gyöngyös, Ungheria, 3200
- Gyongyosi Bugat Pal Korhaz
-
Hódmezővásárhely, Ungheria, 6800
- Porcika Klinika - Vasarhelyi Sarkanyfu Kft.
-
Kaposvár, Ungheria, 7400
- Somogy Varmegyei Kaposi Mor Oktato Korhaz
-
Kecskemét, Ungheria, 6000
- Bacs-kiskun Megyei Korhaz
-
Szolnok, Ungheria, 5000
- Allergo-Derm Bakos Kft.
-
Veszprém, Ungheria, 8200
- Medmare Egeszsegugyi Es Szolgaltato Bt.
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), prior to the first administration of study intervention
- Total body surface area (BSA) greater than or equal to (>=)10 percent (%) at screening and baseline
- Total psoriasis area and severity index (PASI) >=12 at screening and baseline
- Total investigator global assessment (IGA) >=3 at screening and baseline
- Candidate for phototherapy or systemic treatment for plaque psoriasis
Exclusion Criteria:
- Nonplaque form of psoriasis (for example [e.g.], erythrodermic, guttate, or pustular)
- Current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
- Known allergies, hypersensitivity, or intolerance to JNJ-77242113, ustekinumab, or its excipients
- Major surgical procedure within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study
- Transplanted organ (with exception of a corneal transplant greater than [>] 12 weeks before the first administration of study intervention)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Arm 1: JNJ 77242113
Participants will receive JNJ-77242113 once daily from Week 0 through Week 104. All participant will receive ustekinumab matching placebo at Week 0, 4 and 16 to maintain the blind. |
JNJ-77242113 will be administered orally. Matching placebo will be administered subcutaneously. |
|
Comparatore placebo: Arm 2: Placebo
Participants will receive matching placebo for JNJ-77242113 from Week 0 through Week 16, matching placebo for ustekinumab at Week 0, 4 and 16 and JNJ-77242113 from Week 16 through Week 104. |
JNJ-77242113 will be administered orally. Matching placebo will be administered subcutaneously. Matching placebo will be administered orally. |
|
Comparatore attivo: Arm 3: Ustekinumab
Participants will receive Ustekinumab at Week 0, Week 4, and Week 16 followed by JNJ-77242113 once daily from Week 28 through Week 104. Participants will receive both Ustekinumab and placebo for JNJ-77242113 to maintain the blind through Week 28. |
JNJ-77242113 will be administered orally. Matching placebo will be administered orally. Ustekinumab will be administered subcutaneously.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
JNJ-77242113 and Placebo Group: Percentage of Participants with Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater than or Equal to (>=) 2 Grade Improvement from Baseline at Week 16
Lasso di tempo: Week 16
|
IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). |
Week 16
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 16
Lasso di tempo: Week 16
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score. |
Week 16
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 75 Response at Week 16
Lasso di tempo: Week 16
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 75 response represents participants achieving at least a 75 percent improvement from baseline in the PASI score. |
Week 16
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 100 Response at Week 16
Lasso di tempo: Week 16
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score. |
Week 16
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants with IGA Score of 0 at Week 16
Lasso di tempo: Week 16
|
IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). |
Week 16
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with IGA Score of 0 at Week 28
Lasso di tempo: Week 28
|
IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). |
Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 90 Response at Week 28
Lasso di tempo: Week 28
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score. |
Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 100 Response at Week 28
Lasso di tempo: Week 28
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score. |
Week 28
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants with PSSD Symptom Score of 0 at Week 16
Lasso di tempo: Week 16
|
PSSD includes patient-reported outcome (PRO) questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Week 16
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants with >= 4 Point Improvement from Baseline in PSSD Itch Score at Week 16
Lasso di tempo: Week 16
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Week 16
|
|
Number of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs)
Lasso di tempo: Up to Week 108
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. SAE is any untoward medical occurrence that results in: death, is life-threatening, requires in-patient hospitalization/prolongs existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of infectious agent via medicinal product & is medically important. |
Up to Week 108
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants with PSSD Sign Score of 0 at Week 16
Lasso di tempo: Week 16
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. This PRO includes 11 items in total, with 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). A 0 to 10 numerical rating scale for severity is used to rank the psoriasis sign score. A higher score indicates more severe disease. |
Week 16
|
|
JNJ-77242113 and Placebo Group: Change from Baseline in Dermatology Life Quality Index (DLQI) Score at Week 16
Lasso di tempo: Baseline up to Week 16
|
DLQI will be utilized in the adult population and is a dermatology specific health related quality of life (HRQoL) instrument designed to assess the impact of the disease on the HRQoL It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL. |
Baseline up to Week 16
|
|
JNJ-77242113 and Placebo Group: Percentage of Participants with DLQI Score of 0 or 1 at Week 16
Lasso di tempo: Week 16
|
DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL It is a 10 item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL. |
Week 16
|
|
JNJ-77242113 and Placebo Group: Change from Baseline in Body Surface Area (BSA) Score at Week 16
Lasso di tempo: Baseline up to Week 16
|
BSA is a commonly used measure of involvement of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed, (that is., plaque psoriasis). The handprint method for assessing BSA will be used, where the surface area of the participant's hand including the palm and all 5 digits is used as a guide to estimate 1% BSA. |
Baseline up to Week 16
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with >= 4 Point Improvement from Baseline in PSSD Itch Score at Week 28
Lasso di tempo: Week 28
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Change from Baseline in PSSD Sign Score at Week 28
Lasso di tempo: Baseline up to Week 28
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Baseline up to Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Change from Baseline in PSSD Symptom Score at Week 28
Lasso di tempo: Baseline up to Week 28
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Baseline up to Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with PSSD Sign Score of 0 at Week 28
Lasso di tempo: Week 28
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with PSSD Symptom Score of 0 at Week 28
Lasso di tempo: Week 28
|
PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease. |
Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Change from Baseline in DLQI Score at Week 28
Lasso di tempo: Baseline up to Week 28
|
DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL. |
Baseline up to Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with DLQI Score of 0 or 1 at Week 28
Lasso di tempo: Week 28
|
DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL. It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL. |
Week 28
|
|
JNJ-77242113 and Ustekinumab Group: Change from Baseline in BSA Score at Week 16
Lasso di tempo: Baseline up to Week 16
|
BSA is a commonly used measure of involvement of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed, (ie, plaque psoriasis). The handprint method for assessing BSA will be used, where the surface area of the participant's hand including the palm and all 5 digits is used as a guide to estimate 1% BSA. |
Baseline up to Week 16
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with IGA Score of 0 at Week 16
Lasso di tempo: Week 16
|
IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). |
Week 16
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 90 Response at Week 16
Lasso di tempo: Week 16
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score. |
Week 16
|
|
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 100 Response at Week 16
Lasso di tempo: Week 16
|
PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score. |
Week 16
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 77242113PSO3006
- 77242113PSO3006 (Altro identificatore: Janssen Research & Development, LLC)
- 2024-515706-77-00 (Identificatore di registro: EUCT number)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .